© Springer International Publishing AG 2017Daniel C. Baumgart (ed.)Crohn’s Disease and Ulcerative Colitis10.1007/978-3-319-33703-6_58 58. Pediatric Aspects of Inflammatory Bowel Disease Brendan Boyle1 and Jeffrey S. Hyams2, 3 (1) Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children’s…
Time period Important points Preconception – Establish care with multidisciplinary team: primary care physician, obstetrician, maternal–fetal specialist, gastroenterologist – Discontinue medications that may be harmful to fetus (i.e. methotrexate) – Update health care…
© Springer International Publishing AG 2017Daniel C. Baumgart (ed.)Crohn’s Disease and Ulcerative Colitis10.1007/978-3-319-33703-6_42 42. Biologic Therapy in Moderate-to-Severe Ulcerative Colitis: Infliximab Mindy Lam1 and Brian Bressler1 (1) Division of Gastroenterology, University of British Columbia, Vancouver, BC,…
Study Corticosteroid (starting dose) Comparator No. of patients Disease extent Duration (weeks) End-points Remission NNT (95 % CI) Intravenous Meyers [6] 1983 Hydrocortisone (300 mg daily) Corticotropin (ACTH) 120 U/day…
Fig. 31.1 Methotrexate (MTX) metabolism . MTX and its polyglutamate metabolites (MTXPG) potently inhibit dihydrofolate reductase (DHFR), impairing the conversion of dihydrofolate (FH2) to tetrahydrofolate (FH4). MTXPG also inhibit folate-dependent…
© Springer International Publishing AG 2017Daniel C. Baumgart (ed.)Crohn’s Disease and Ulcerative Colitis10.1007/978-3-319-33703-6_29 29. Steroid Therapy for Crohn’s Disease A. Hillary Steinhart1 (1) IBD Centre, Mount Sinai Hospital and Department of Medicine, University of Toronto, Room…
© Springer International Publishing AG 2017Daniel C. Baumgart (ed.)Crohn’s Disease and Ulcerative Colitis10.1007/978-3-319-33703-6_28 28. Conventional Medical Management of Crohn’s Disease: Sulfasalazine Miquel A. Gassull1, 2 and Eduard Cabré3, 4 (1) Health Science Research Institute, Germans Trias i…
1. Approximately one third of patients has chronically active disease or fluctuating disease and hence this is the cohort most likely to be treated by more aggressive immunomodulating therapy. However,…
Fig. 25.1 Conceptual model of variables influencing quality of life in inflammatory bowel disease (reprinted from ref. [16] with permission from John Wiley & Sons, Inc.) While most studies of…
Stool frequency a 0: Normal 1: Number of stools for this patient 1–2 stools more than normal 2: 3–4 stools more than normal 3: 5 or more stools more than…
